Jakafi Side Effects
Generic Name: ruxolitinib
Note: This page contains information about the side effects of ruxolitinib. Some of the dosage forms included on this document may not apply to the brand name Jakafi.
Not all side effects for Jakafi may be reported. You should always consult a doctor or healthcare professional for medical advice. Side effects can be reported to the FDA here.
For the Consumer
Applies to ruxolitinib: oral tablet
In addition to its needed effects, some unwanted effects may be caused by ruxolitinib (the active ingredient contained in Jakafi). In the event that any of these side effects do occur, they may require medical attention.
You should check with your doctor immediately if any of these side effects occur when taking ruxolitinib:More common
- Black, tarry stools
- bladder pain
- bleeding gums
- blood in the urine or stools
- cloudy urine
- collection of blood under the skin
- deep, dark purple bruise
- difficult, burning, or painful urination
- frequent urge to urinate
- itching, pain, redness, or swelling
- large, flat, blue or purplish patches in the skin
- lower back or side pain
- painful or difficult urination
- pale skin
- pinpoint red spots on the skin
- pus in the urine
- shortness of breath
- small, red or purple spots on the skin
- sore throat
- troubled breathing with exertion
- ulcers, sores, or white spots in the mouth
- unusual bleeding or bruising
- unusual tiredness or weakness
- Painful blisters on the trunk of the body
Some of the side effects that can occur with ruxolitinib may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:More common
- Bloated or full feeling
- dizziness or lightheadedness
- excess air or gas in the stomach or intestines
- feeling of constant movement of self or surroundings
- passing gas
- sensation of spinning
- weight gain
For Healthcare Professionals
Applies to ruxolitinib: oral tablet
Dermatologic side effects have included bruising (23.2%).
Gastrointestinal side effects have included flatulence (5.2%).
Genitourinary side effects have included urinary tract infections (9.0%).
Hematologic side effects have included anemia (96.1%), thrombocytopenia (69.7%), and neutropenia (18.7%).
Immunologic side effects have included herpes zoster (1.9%).
Metabolic side effects have included weight gain (7.1%).
Laboratory abnormalities have included alanine transaminase (ALT) abnormalities (25.2%), aspartate transaminase (AST) abnormalities (17.4%), and elevated cholesterol levels (16.8%).
Nervous system side effects have included dizziness (18.1%), and headache (14.8%).
More about Jakafi (ruxolitinib)
Related treatment guides
Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.